Calidi Biotherapeutics Prices $5.2 Mln Public Offering Of Shares And Warrants

Calidi Biotherapeutics priced an underwritten public offering of 10.52 million units at $0.50 per unit, implying gross proceeds of approximately $5.26 million. Each unit consists of one share of common stock or a pre-funded warrant, creating potential dilution upon issuance/exercise. This is a routine equity financing to raise liquidity for the biotech and is unlikely to have market-wide impact.

Analysis

Calidi Biotherapeutics priced an underwritten public offering of 10.52 million units at $0.50 per unit, implying gross proceeds of approximately $5.26 million. Each unit consists of one share of common stock or a pre-funded warrant, creating potential dilution upon issuance/exercise. This is a routine equity financing to raise liquidity for the biotech and is unlikely to have market-wide impact.